Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
2022年1月10日 - 8:30PM
ビジネスワイヤ(英語)
Expands Pfizer’s access to lipid nanoparticle
(LNP) formulation technology, offering a strong strategic fit with
Pfizer’s mRNA strategy
Pfizer gains option to license Acuitas’ LNP
technology for up to 10 targets for vaccine or therapeutic
development
Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company
focused on developing lipid nanoparticle (LNP) delivery systems to
enable messenger RNA (mRNA)-based therapeutics, today announced
they have entered into a Development and Option agreement under
which Pfizer will have the option to license, on a non-exclusive
basis, Acuitas’ LNP technology for up to 10 targets for vaccine or
therapeutic development.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220110005255/en/
Acuitas’ clinically-validated LNP technology is used in
COMIRNATY®, the Pfizer-BioNTech COVID-19 vaccine.
“Our swift delivery of the world’s first mRNA-LNP-based vaccine
made clear the promise of mRNA-LNP technology,” said Mikael
Dolsten, M.D., Ph.D., Chief Scientific Officer and President,
Worldwide Research, Development and Medical of Pfizer Inc. “We are
making significant investments to harness the power of the mRNA-LNP
technology and deliver potential new breakthrough vaccines and
therapeutics that address significant unmet needs for patients.
This agreement expands our LNP capabilities and allows us to
explore more projects within our existing vaccines area and new
therapeutic areas where mRNA-LNP technology holds potential for
success.”
“Acuitas is extremely proud that its LNP technology contributes
to the success of COMIRNATY® and is excited to be working with
Pfizer to advance new vaccines and therapeutic products,” said Dr.
Thomas Madden, President & CEO of Acuitas Therapeutics.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 170 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.Pfizer.com. In addition, to
learn more, please visit us on www.Pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
About Acuitas Therapeutics
Founded in February 2009, Vancouver-based Acuitas Therapeutics
(www.acuitastx.com) is a private biotechnology company that
specializes in the development of delivery systems for nucleic acid
therapeutics based on lipid nanoparticles. The company partners
with pharmaceutical and biotechnology companies and academic
institutes to advance nucleic acid therapeutics into clinical
trials and to the marketplace. The team works with partners to
develop new therapies to address unmet clinical needs based on its
internationally recognized capabilities in delivery technology.
Acuitas Therapeutics has agreements in place with several partners
to use its proprietary lipid nanotechnology in the development of
COVID-19 vaccines. These include Pfizer/BioNTech for COMIRNATY®,
which has received full approval in the U.S. and Canada and is
authorized for Emergency Use in Europe, the UK and many other
countries.
Pfizer Disclosure Notice
The information contained in this release is as of January 10,
2022. Pfizer assumes no obligation to update forward-looking
statements contained in this release as the result of new
information or future events or developments.
This release contains forward-looking information about the
potential of mRNA-LNP technology and a development and option
agreement under which Pfizer will have the option to license, on a
non-exclusive basis, Acuitas’ LNP technology for up to 10 targets
for vaccine or therapeutic development, including their potential
benefits, that involves substantial risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied by such statements. Risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including the ability to meet anticipated clinical
endpoints, commencement and/or completion dates for clinical
trials, regulatory submission dates, regulatory approval dates
and/or launch dates, as well as the possibility of unfavorable new
clinical data and further analyses of existing clinical data; the
risk that clinical trial data are subject to differing
interpretations and assessments by regulatory authorities; whether
regulatory authorities will be satisfied with the design of and
results from our clinical studies; whether and when any
applications may be filed for any drug or vaccine candidates in any
jurisdictions; whether and when regulatory authorities may approve
any potential applications that may be filed for any drug or
vaccine candidates in any jurisdictions, which will depend on
myriad factors, including making a determination as to whether the
product’s benefits outweigh its known risks and determination of
the product’s efficacy and, if approved, whether any such drug or
vaccine candidates will be commercially successful; decisions by
regulatory authorities impacting labeling, manufacturing processes,
safety and/or other matters that could affect the availability or
commercial potential of any drug or vaccine candidates; whether the
agreement between Pfizer and Acuitas will be successful;
uncertainties regarding the impact of COVID-19 on Pfizer’s
business, operations and financial results; and competitive
developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2020 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220110005255/en/
Pfizer Media Contact:
PfizerMediaRelations@Pfizer.com
+1 (212) 733-1226
Pfizer Investor Contact: IR@Pfizer.com +1 (212) 733-4848
Acuitas Therapeutics Media
Contact: +1 (604) 846-8461 paul@ahacreative.com
Pfizer (NYSE:PFE)
過去 株価チャート
から 3 2024 まで 4 2024
Pfizer (NYSE:PFE)
過去 株価チャート
から 4 2023 まで 4 2024